1. Nagpal M, Singh S, Singh P, Chauhan P, Zaidi MA. Tumor markers: A diagnostic tool. Natl J Maxillofac Surg. 2016 Jan-Jun;7(1):17-20. doi: 10.4103/0975-5950.196135. PMID: 28163473; PMCID: PMC5242068.
2. Yang Y, Jiang X, Liu Y, Huang H, Xiong Y, Xiao H, Gong K, Li X, Kuang X, Yang X. Elevated tumor markers for monitoring tumor response to immunotherapy. EClinicalMedicine. 2022 Apr 8;46:101381. doi: 10.1016/j.eclinm.2022.101381. PMID: 35434583; PMCID: PMC9011015.
3. Su BB, Shi H, Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol. 2012 May 7;18(17):2121-6. doi: 10.3748/wjg.v18.i17.2121. PMID: 22563201; PMCID: PMC3342612.
4. Sekiguchi M, Matsuda T. Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening. Sci Rep. 2020 Oct 23;10(1):18202. doi: 10.1038/s41598-020-75319-8. PMID: 33097814; PMCID: PMC7585432.
5. Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, Frizelle F. A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. Ann Coloproctol. 2019 Dec;35(6):294-305. doi: 10.3393/ac.2019.11.13. Epub 2019 Dec 31. PMID: 31937069; PMCID: PMC6968721.
6. Pin-Vieito N, Iglesias MJ, Remedios D, Álvarez-Sánchez V, Fernández-Bañares F, Boadas J, Martínez-Bauer E, Campo R, Bujanda L, Ferrández Á, Piñol V, Rodríguez-Alcalde D, Menéndez-Rodríguez M, García-Morales N, Pérez-Mosquera C, Cubiella J. Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort. Diagnostics (Basel). 2020 Dec 2;10(12):1036. doi: 10.3390/diagnostics10121036. PMID: 33276621; PMCID: PMC7770570.
7. Sørensen CG, Karlsson WK, Pommergaard HC, Burcharth J, Rosenberg J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence - A systematic review. Int J Surg. 2016 Jan;25:134-44. doi: 10.1016/j.ijsu.2015.11.065. Epub 2015 Dec 15. PMID: 26700203.
8. Kabel AM. Tumor markers of breast cancer: New prospectives. Journal of Oncological Sciences, 2017. 3(1), 5–11. doi:10.1016/j.jons.2017.01.001
9. Ren W, Chen M, Qiao Y, Zhao F. Global guidelines for breast cancer screening: A systematic review. Breast. 2022 Aug;64:85-99. doi: 10.1016/j.breast.2022.04.003. Epub 2022 Apr 19. PMID: 35636342; PMCID: PMC9142711.
10. Lian M, Zhang C, Zhang D, Chen P, Yang H, Yang Y, Chen S, Hong G. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer. J Clin Lab Anal. 2019 Jun;33(5):e22875. doi: 10.1002/jcla.22875. Epub 2019 Mar 6. PMID: 30843272; PMCID: PMC6595372.
11. Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, Cardoso F. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017 Apr;75:284-298. doi: 10.1016/j.ejca.2017.01.017. Epub 2017 Feb 28. PMID: 28259011.
12. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019 Mar 27;12(1):28. doi: 10.1186/s13048-019-0503-7. PMID: 30917847; PMCID: PMC6436208.
13. Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and Ovarian Cancer: A Comprehensive Review. Cancers (Basel). 2020 Dec 11;12(12):3730. doi: 10.3390/cancers12123730. PMID: 33322519; PMCID: PMC7763876.
14. Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 2020 Oct 28;17(10):e1003295. doi: 10.1371/journal.pmed.1003295. PMID: 33112854; PMCID: PMC7592785.
15. Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K. Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). EJIFCC. 2014 Apr 28;25(1):55-78. PMID: 27683457; PMCID: PMC4975191.
16. Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, Agoritsas T, Dahm P. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018 Sep 5;362:k3519. doi: 10.1136/bmj.k3519. PMID: 30185521; PMCID: PMC6283370.
17. Tikkinen KAO, Dahm P, Lytvyn L, Heen AF, Vernooij RWM, Siemieniuk RAC, Wheeler R, Vaughan B, Fobuzi AC, Blanker MH, Junod N, Sommer J, Stirnemann J, Yoshimura M, Auer R, MacDonald H, Guyatt G, Vandvik PO, Agoritsas T. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ. 2018 Sep 5;362:k3581. doi: 10.1136/bmj.k3581. PMID: 30185545; PMCID: PMC6283372.
18. Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan D, Cao X, Han M, Du H, Ye Y. The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 2020 Feb 13;15(2):e0228857. doi: 10.1371/journal.pone.0228857. PMID: 32053643; PMCID: PMC7018038.
19. Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD013346. doi: 10.1002/14651858.CD013346.pub2. PMID: 33855699; PMCID: PMC8078581.
20. Scarà S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:247-60. doi: 10.1007/978-94-017-7215-0_15. PMID: 26530370.
21. Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 - tumor marker: Past, present, and future. World J Gastrointest Surg. 2020 Dec 27;12(12):468-490. doi: 10.4240/wjgs.v12.i12.468. PMID: 33437400; PMCID: PMC7769746.